Table 1.
Demographic and baseline clinical measurements in subjects with the designated length of follow-up.
| Subjects with | Subjects with | Subjects with | Subjects with | |
|---|---|---|---|---|
| 6 months F/U | 12 months F/U | 18 months F/U | 24 months F/U | |
| N | 230 | 222 | 164 | 177 |
| Male (%) | 140 (60.87%) | 138 (62.16%) | 106 (64.63%) | 104 (58.76%) |
| Hispanic (%) | 18 (8.14%), n = 221 | 16 (7.48%), n = 214 | 15 (9.38%), n = 160 | 13 (7.69%), n = 169 |
| Age | 65.75 (34.75–85.58) | 66.46 (34.75–85.58) | 64.62 (34.75–85.58) | 66.92 (34.75–85.58) |
| Years of education | 16 (9–20), n = 228 | 16 (9–20), n = 220 | 16 (9–20), n = 162 | 16 (9–20), n = 175 |
| Disease duration | 4 (0–21) | 4 (0–21) | 4 (0–19) | 4 (0–21) |
| Baseline measurements | ||||
| MDS-UPDRS | ||||
| Part I | 8 (0–22) | 8 (0–22) | 7 (0–20) | 8 (0–22) |
| Part II | 8 (0–30) | 8 (0–30) | 7 (0–30) | 7 (0–30) |
| Part III | 17 (2–70) | 17 (2–70) | 16 (3–54) | 17 (3–70) |
| Part IV | 0 (0–20) | 0 (0–20) | 0 (0–20) | 0 (0–20) |
| Total Score | 36 (7–104) | 36 (7–104) | 32 (8–104) | 35 (8–104) |
| Hoehn & Yahr | 2 (1–4) | 2 (1–4) | 2 (1–4) | 2 (1–4) |
| LEDD | 600 (60–2,508.5) | 600 (60–2,508.5) | 563.75 (60–2,508.5) | 600 (60–2,508.5) |
| S&E | 0.9 (0.4–1) | 0.9 (0.6–1) | 0.9 (0.6–1) | 0.9 (0.6–1) |
| MoCA | 27 (17–31) | 27 (17–30) | 27.5 (17–30) | 27 (17–30) |
| HAM-A | 6.5 (0–29) | 7 (0–29) | 5 (0–27) | 6 (0–29) |
| HAM-D | 4 (0–23), n = 227 | 4 (0–23), n = 219 | 3.5 (0–23) | 4 (0–23) |
| Epworth | 7 (0–21) | 7 (0–21) | 6 (0–21) | 7 (0–21) |
| UPSIT | 18 (6–39), n = 228 | 18 (6–39), n = 219 | 18 (6–39), n = 163 | 18 (6–39), n = 174 |
| GCO | −0.1 (−1.25 to 2.1) | −0.09 (−1.25 to 2.1) | −0.21 (−1.23 to 2.1) | −0.12 (−1.25 to 2.1) |
| PDQ-39 Mobility | 5 (0–87.5), n = 229 | 7.5 (0–67.5), n = 221 | 5 (0–67.5), n = 163 | 6.25 (0–67.5), n = 176 |
MDS-UPDRS: Movement Disorders Society revision of the Unified Parkinson Disease Rating Scale; LEDD: Levodopa equivalent daily dose; S&E: Schwab and England Activities of Daily Living Scale; MoCA: Montreal Cognitive Assessment; HAM-A: Hamilton Anxiety Scales; HAM-D: Hamilton Depression Rating Scale; Epworth: Epworth Sleepiness Scale; UPSIT: University of Pennsylvania Smell Identification Test; GCO: Global Composite Outcome; PDQ-39 Mobility: Mobility subscale of the Parkinson's Disease Questionnaire. Cells containing “n=” denote the sample size of subjects with available data.